title: Resveratrol prevents streptozotocin-induced diabetes by inhibiting the apoptosis of pancreatic β-cell and the cleavage of poly (ADP-ribose) polymerase.
abstract: Resveratrol (3,5,4'-trihydroxystilbene; RSV) is one kind of polyphenolic phytoalexin that has many effects on metabolic diseases.  This study aimed to evaluate the protective effect of RSV pretreatment on β-cell.  Male Sprague Dawley rats weighing 200-230 g were divided into 4 groups: (1) RSV; (2) streptozotocin (STZ, 70 mg/kg, intraperitoneally); (3) STZ after 7 days pretreatment with RSV; and (4) STZ pretreated with nicotinamide.  Fasting glucose concentration was measured and an intraperitoneal glucose tolerance test was performed 72 h after STZ injection to determine the diabetic condition.  The pancreas was removed 3, 6, 36, and 48 h after STZ injection.  STZ induced diabetes in all rats not given RSV pretreatment, whereas none of the RSV-pretreated rats developed diabetes.  Pretreatment with RSV inhibited apoptosis and reduced the activation of caspase-3 and poly(ADP-ribose) polymerase (PARP).  However, expression of the total length PARP was not affected by pretreatment.  Our findings suggest that RSV protects β-cells from STZ simultaneously with inhibiting the activation of PARP.
authors: Endocrinology, Severance Hospital Integrative Research Institute for Cerebral & Cardiovascular Diseases, Yonsei University College of Medicine, Seoul, Korea.
authors: Cheol Ryong
authors: CR
authors: Ku
authors: Hyeon Jeong
authors: HJ
authors: Lee
authors: Suk Kyoung
authors: SK
authors: Kim
authors: Eun Young
authors: EY
authors: Lee
authors: Mi-Kyung
authors: MK
authors: Lee
authors: Eun Jig
authors: EJ
authors: Lee
mesh_terms: D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects*; D001786:Blood Glucose / Q000032:analysis; D053148:Caspase 3 / Q000378:metabolism; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D004789:Enzyme Activation / Q000187:drug effects*; D005951:Glucose Tolerance Test; D006943:Hyperglycemia / Q000517:prevention & control; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D020287:In Situ Nick-End Labeling; D050417:Insulin-Secreting Cells / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D008297:Male; D000071137:Poly (ADP-Ribose) Polymerase-1; D011065:Poly(ADP-ribose) Polymerases / Q000378:metabolism*; D059748:Proteolysis / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D000077185:Resveratrol; D013267:Stilbenes / Q000627:therapeutic use*; D013311:Streptozocin; D013997:Time Factors
chemical_list: D000975:Antioxidants; D001786:Blood Glucose; D007004:Hypoglycemic Agents; D013267:Stilbenes; D013311:Streptozocin; C499322:Parp1 protein, rat; D000071137:Poly (ADP-Ribose) Polymerase-1; D011065:Poly(ADP-ribose) Polymerases; C505410:Casp3 protein, rat; D053148:Caspase 3; D000077185:Resveratrol